<DOC>
	<DOC>NCT01492153</DOC>
	<brief_summary>This study is conducted in Asia. The aim of this study is to investigate the safety and efficacy of NovoLet® human insulin delivery system in an outpatient setting.</brief_summary>
	<brief_title>NovoLet® Surveillance Study on Using Human Insulin System in Indonesia</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin, beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Isophane Insulin, Human</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 1 diabetes mellitus Type 2 diabetes mellitus Other types of diabetes mellitus (gestational, drug induced [thiazide] or metabolic syndromerelated)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>